Document Detail


Effects of Celecoxib On Restenosis after Coronary Intervention and Evolution of Atherosclerosis (Mini-COREA) Trial: celecoxib, a double-edged sword for patients with angina.
MedLine Citation:
PMID:  22408034     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
AimsIn the previous COREA-TAXUS trial, a 6-month adjunctive use of celecoxib reduced target-lesion revascularization (TLR) without increased thrombotic risk. We aimed to confirm the effects of 3-month celecoxib in patients receiving drug-eluting stent (DES) implantation in the larger prospective, randomized trial.Methods and resultsPatients (n = 909) treated for native coronary lesions were randomized into four groups: the control or the celecoxib group with stratification by stents: paclitaxel-eluting stent (PES) or zotarolimus-eluting stent (ZES). In the celecoxib group, 200 mg of celecoxib was given twice daily for 3 months after the procedure. The primary endpoint was in-stent late loss (LL) at 6 months. In-stent LL was significantly lower in the celecoxib group than the control group (0.64 ± 0.54 vs. 0.55 ± 0.47 mm, P = 0.02). The trend of LL reduction in the celecoxib group was maintained in the ZES and PES subgroups, although it did not reach statistical significance. There was a trend towards the reduced clinically driven TLR in the celecoxib group (5.7 vs. 3.2%, log-rank P = 0.09), but adverse cardiac events rate did not differ between the two groups (composite of cardiac death, non-fatal myocardial infarction, and TLR; 8.6 vs. 7.7%, log-rank P = 0.84). Non-fatal myocardial infarction and cardiac death occurred in 1.6% of the patients in the celecoxib group when compared with 0.2% in the control group (log-rank P = 0.03).ConclusionThree-month adjunctive celecoxib would be useful to reduce LL of DES. However, this study may raise the concern about increased thrombotic risk with celecoxib even in patients receiving dual anti-platelet therapy.
Authors:
Hyun-Jae Kang; Il-Young Oh; Jin-Wook Chung; Han-Mo Yang; Jung-Won Suh; Kyung Woo Park; Taek Keun Kwon; Hae-Young Lee; Young-Seok Cho; Tae-Jin Youn; Bon-Kwon Koo; Won-Yu Kang; Weon Kim; Seung-Woon Rha; Jang Ho Bae; In-Ho Chae; Dong-Ju Choi; Hyo-Soo Kim
Related Documents :
21382074 - Quantification of left ventricular longitudinal strain, strain rate, velocity, and disp...
22458574 - Bivalirudin for primary percutaneous coronary intervention in acute myocardial infarcti...
18515284 - Antibodies with beta-adrenergic activity from chronic chagasic patients modulate the qt...
22121044 - The prognostic role of mitral regurgitation after primary percutaneous coronary interve...
6407314 - Intravenous nitroglycerin in acute myocardial infarction.
1430354 - Effectiveness of various barrier preparations in preventing and/or ameliorating experim...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-3-8
Journal Detail:
Title:  European heart journal     Volume:  -     ISSN:  1522-9645     ISO Abbreviation:  -     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-3-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Seoul National University Hospital, Seoul, Republic of Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical experience of entirely subcutaneous implantable cardioverter-defibrillators in children and...
Next Document:  Imaging the right heart: the use of integrated multimodality imaging.